TY - JOUR
T1 - Current perspectives on bioresorbable scaffolds in coronary intervention and other fields
AU - Wu, Xinlei
AU - Wu, Sijing
AU - Kawashima, Hideyuki
AU - Hara, Hironori
AU - Ono, Masafumi
AU - Gao, Chao
AU - Wang, Rutao
AU - Lunardi, Mattia
AU - Sharif, Faisal
AU - Wijns, William
AU - Serruys, Patrick W.
AU - Onuma, Yoshinobu
N1 - Funding Information: This paper was supported by the Natural Science Foundation of Zhejiang Province, China (LQ20H180004) and Science Foundation Ireland (RSF 1413). Publisher Copyright: © 2021 Informa UK Limited, trading as Taylor & Francis Group. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021
Y1 - 2021
N2 - Introduction: The first-generation bioresorbable scaffolds (BRSs) had a large strut profile to compensate for the insufficient radial strength of bioresorbable polymer materials, resulting in higher scaffold thrombosis rates than conventional drug-eluting stents. To improve the clinical safety and efficacy, the new generation BRSs have been improved by optimal structure design, post-processing of bioresorbable polymer materials, or altering bioresorbable metallic alloys. Areas covered: This review summarizes the lessons learned from the first-generation BRS, updates the clinical outcomes of trials evaluating ABSORB bioresorbable vascular scaffold at long-term and bioresorbable metallic alloy-based devices, and examines recent outcomes of BRS treated in STEMI patients. This review also provides an overview of the current clinical data of seven BRSs manufactured in Asia, and of the BRSs extended application in other clinical arenas. Expert opinion: Drawbacks of the first-generation BRSs need to be addressed by the next generation of these stents with novel materials and technologies. Clinical research, including randomized controlled trials, are required to further evaluate BRSs application in coronary artery disease. The encouraging results of BRSs innovation applied in the peripheral arteries and gastrointestinal tracts support other potential clinical applications of BRS technology.
AB - Introduction: The first-generation bioresorbable scaffolds (BRSs) had a large strut profile to compensate for the insufficient radial strength of bioresorbable polymer materials, resulting in higher scaffold thrombosis rates than conventional drug-eluting stents. To improve the clinical safety and efficacy, the new generation BRSs have been improved by optimal structure design, post-processing of bioresorbable polymer materials, or altering bioresorbable metallic alloys. Areas covered: This review summarizes the lessons learned from the first-generation BRS, updates the clinical outcomes of trials evaluating ABSORB bioresorbable vascular scaffold at long-term and bioresorbable metallic alloy-based devices, and examines recent outcomes of BRS treated in STEMI patients. This review also provides an overview of the current clinical data of seven BRSs manufactured in Asia, and of the BRSs extended application in other clinical arenas. Expert opinion: Drawbacks of the first-generation BRSs need to be addressed by the next generation of these stents with novel materials and technologies. Clinical research, including randomized controlled trials, are required to further evaluate BRSs application in coronary artery disease. The encouraging results of BRSs innovation applied in the peripheral arteries and gastrointestinal tracts support other potential clinical applications of BRS technology.
KW - Drug-eluting stents
KW - bioresorbable scaffold
KW - gastrointestinal system
KW - new generation scaffold
KW - peripheral artery disease
UR - http://www.scopus.com/inward/record.url?scp=85103415206&partnerID=8YFLogxK
U2 - https://doi.org/10.1080/17434440.2021.1904894
DO - https://doi.org/10.1080/17434440.2021.1904894
M3 - Review article
C2 - 33739213
SN - 1743-4440
VL - 18
SP - 351
EP - 365
JO - Expert review of medical devices
JF - Expert review of medical devices
IS - 4
ER -